These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6723758)

  • 1. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
    Hammarlund MM; Paalzow LK; Odlind B
    Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furosemide kinetics in renal failure.
    Tilstone WJ; Fine A
    Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and absolute bioavailability of furosemide in healthy males.
    Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT
    J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
    Cheng H; Leff JA; Amin R; Gertz BJ; De Smet M; Noonan N; Rogers JD; Malbecq W; Meisner D; Somers G
    Pharm Res; 1996 Mar; 13(3):445-8. PubMed ID: 8692739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of furosemide in patients with congestive heart failure.
    Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
    Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.
    Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1983 Dec; 11(6):623-40. PubMed ID: 6678312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the fate of furosemide in man.
    Beermann B; Dalén E; Lindström B; Rosén A
    Eur J Clin Pharmacol; 1975 Oct; 9(1):51-61. PubMed ID: 1233253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.
    Uchino K; Isozaki S; Amano J; Tanaka N; Saitoh Y; Nakagawa F; Tamura Z; Oka H
    J Pharmacobiodyn; 1983 Sep; 6(9):684-91. PubMed ID: 6655548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius).
    Ali BH; Wong YC; Alhadrami GA; Charles BG; Bashir AK
    Res Vet Sci; 1998; 64(1):69-72. PubMed ID: 9557809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent pharmacokinetics of furosemide in the rat.
    Hammarlund MM; Paalzow LK
    Biopharm Drug Dispos; 1982; 3(4):345-59. PubMed ID: 7159689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.
    Bastain W; Boyce MJ; Stafford LE; Morton PB; Clarke DA; Marlow HF
    Eur J Clin Pharmacol; 1988; 34(5):469-73. PubMed ID: 2904884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.
    Rogers HJ; Morrison P; House FR; Bradbrook ID
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):8-11. PubMed ID: 7056605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
    McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
    Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition kinetics of furosemide in dogs.
    El-Sayed MG; Atef M; El-Gendi AY; Youssef SA
    Arch Int Pharmacodyn Ther; 1981 Sep; 253(1):4-10. PubMed ID: 7325754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
    Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
    Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.